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The efﬁciency of the deprotocuprationearoylation of 2-chloropyridine using lithiocuprates prepared
from CuX (X¼Cl, Br) and LiTMP (TMP¼2,2,6,6-tetramethylpiperidido, 2 equiv) was investigated. CuCl was
identiﬁed as a more suitable copper source than CuBr for this purpose. Different diaryl ketones bearing
a halogen at the 2 position of one of the aryl groups were synthesized in this way from azines and
thiophenes. These were then involved in palladium-catalyzed ring closure: substrates underwent ex-
pected CH-activation-type arylation to afford ﬂuorenone-type compounds, and were also subjected to
cyclization reactions leading to xanthones, notably in the presence of oxygen-containing substituents or
reagents.
 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Due to the biological interest of azaﬂuorenones, for example, in
relation to their antifungal,1 antimicrobial,2 antimalarial,2b,3 and
cytotoxic2b,4 properties, or else for their role in the treatment of
neurodegenerative disorders,5 many studies have been devoted to
their synthesis. Among modern synthetic methods by which to
access them, lithiations6 and multicomponent reactions2d,4a,7 can
be cited. In 2010, Kraus and Kempema developed an approach us-
ing 2-bromoaryl 3-pyridyl ketones, prepared by reaction of 3-
pyridyllithiums with 2-bromobenzaldehydes followed by oxida-
tion, in intramolecular Heck cyclization reactions.2c Facile oxidationr the terms of the Creative
tricted use, distribution, and
thor and source are credited.
ail addresses: valerie.thiery@
heatley), ﬂorence.mongin@
. Published by Elsevier Ltd. All righof the corresponding a-aryl-a-(2-bromo-3-pyridyl)methanols led
Ray and co-workers to successfully perform, within one step, both
oxidation and cyclization reactions.8
In the course of the development of lithium 2,2,6,6-
tetramethylpiperidido (LiTMP) bases for the deprotonative metal-
lation of aromatic compounds,9 we have developed the use of the
lithiocuprates prepared in situ from CuCl and LiTMP (2 equiv).10
Besides its possible use at rt, one main advantage of using the
resulting bimetallic base is the possible trapping of the formed
arylmetal species by aroyl chlorides to directly afford ketones. Ap-
plied to the synthesis of 2-chloro diaryl ketones, this method could
be combined with direct arylation through CeH bond activation by
intramolecular transitionmetal-catalysis,11 to afford azaﬂuorenones
and related compounds. We have recently demonstrated the feasi-
bility of this two-step access to such tricyclic heterocycles;12 herein,
thedetails of our investigations, including the testingof a large range
of substrates, and the unexpected outcomes observed for the cycli-
zation reactions are described.ts reserved.
Fig. 1. ORTEP diagram (50% probability, H atoms omitted) of the dimer of (TMP)2Cu-
Li$LiBr (B).
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Before embarking on a study aimed at using the depro-
tocuprationearoylation sequence as the main step in the synthesis
of azaﬂuorenones and related compounds, we sought to investigate
what the best source of lithiocuprate base might be. This could
conceivably involve preparation of the cuprate in situ from CuX
(X¼F, Cl, Br, I) and LiTMP (2 equiv) at 0 C in THF containing TMEDA
(1 equiv, TMEDA¼N,N,N0,N0-tetramethylethylenediamine).10c
Prior work on the deprotometalationeiodination of benzox-
azole involved the use of a (TMP)2ZneTMPLi mixture and afforded
only a 2% difference in yield between the quenched products when
the basewas prepared fromZnBr2 (58% yield) or ZnCl2 (60% yield).13
In a similar way, the putative base (TMP)3FeLi gave approximately
equivalent yields (80% using FeCl2 vs 86% with FeBr2),14 suggesting
essentially equivalent reactivities for these two halides. In contrast,
prior work with FeI2 clearly gave a lower yield (62%) and it proved
substantially worse with FeF2 (27%).14 On the back of these data we
tested both CuCl and CuBr as potential substrates in the present
study; 2-chloropyridine was reacted with bases generated using
either copper(I) halide at rt for 2 h before interception of the cor-
responding arylmetal reagents with different benzoyl chlorides. In
linewith expectation, lithiocuprates generated using CuBr and CuCl
achieved essentially similar yields (Table 1). However, it was noted
that, reproducibly, chloride reagents performed slightly better and
these were therefore selected for more detailed study (vide infra).
This notwithstanding, the isolation and full characterization of
Lipshutz-type (TMP)2CuLi$LiBr (B) (Fig. 1) suggests that it is iso-
structural with the known chloride12 analogue, so that the nominal
differences observed in product yield are unlikely to be attributable
to lithiocuprate structure based on the choice of bromide or chlo-
ride starting material.
Based on the prior work with CuF and CuI, and on the data in
Table 1, CuCl was selected for preparing the lithiocuprate for use
in subsequent deprotocupration-aroylation work. The technique
to be used has previously been applied to the synthesis of the
heterocyclic ketones 1,10b 4,10c 5,10b 610b and 7,10b and has been
successfully used to reach the diaryl ketones 8e15. All theseTable 1
Deprotocupration of 2-chloropyridine using in situ prepared (TMP)2CuLi$LiCl (A) or (TM
1) (TMP)2CuLi·LiX
TMEDA (1 eq
THF, rt, 2 h 2)N Cl
2 LiTMP
Cu
Entry ClCOAr CuX (base)
1 ClCOPh CuCl (A)
2 CuBr (B)
3
Cl
O
OMe
CuCl (A)
4 CuBr (B)
5
Cl
O
Cl
CuCl (A)
6 CuBr (B)
a Yield after puriﬁcation by column chromatography. The rest is starting material.
b Reaction performed at least twice.compounds, gathered in Table 2, could lead to heterocyclic tri-
cycles (or tetracycle in the case of 4) through cyclizing arylation.
It is worth noting that the trapping step was improved in the
thiophene series by raising the reaction temperature to 60 C
(entry 14).
We subsequently turned our attention to the cyclization of the
halogeno diaryl ketones, using them to yield azaﬂuorenones and
related compounds through palladium-catalyzed intramolecular
arylation. The synthesis of 4-azaﬂuorenone (16) has previously
been the subject of several studies,6b,15 and harsh conditions are
known to sometimes be required for its formation. For example,
Stauffer and co-workers prepared it by heating 2-phenylnicotinic
acid (obtained in two steps from 2-chloro-3-cyanopyridine) at
190 C in polyphosphoric acid.16 To attempt the conversion of 3-
benzoyl-2-chloropyridine (1) to the tricycle 16, we used a pro-
tocol previously described for the cyclization of 2-chloro diaryl
aniline to carbazole as a basis for this.17 The reactions were carried
out in the presence of catalytic amounts of Pd(OAc)2, an electron-P)2CuLi$LiBr (B) followed by benzoylation
(1 equiv)
uiv)
ClCOAr N
COAr
1-3
Cl
X
Product Yielda (%)
1
N
COPh
Cl
78e90b,10
60e70b
2
N Cl
O
OMe
60e80b
49
3
N Cl
O
Cl
56e80b
55e61b
Table 2
Synthesis of the diaryl ketones 1e15 by deprotocupration followed by aroylation
1) (TMP)2CuLi·LiCl (1 equiv)
TMEDA (1 equiv)
THF, rt, 2 h 2) ClCOAr'
1-3
Ar H Ar
O
Ar'
Entry AreH ClCOAr0 R and/or X Product Yielda (%)
1
N
H
Cl
Cl
O
X
R
2
4
3
H, CH 1
N Cl
O
X
R
2
4
3
9010b
2 4-OMe, CH 2 80
3 4-Cl, CH 3 80
4 3-OMe, CH 8 66
5 2-Cl, CH 9 59
6 2-Cl, N 10 65
7
N
H
Cl
ClCOPh 4
N
COPh
Cl
4410c
8
N
H
OMe
Cl
O
X
R Cl, CH 11
N OMe
O
X
R 56
9 Br, CH 12 43
10 Cl, N 13 39
11
N
H
OMeMeO
Cl
O Cl
5
N OMe
O Cl
MeO
9110b
12
N
H
OMe
Cl
O Cl
6 N
OMe
O Cl
5710b
13
N
N
H
OMeMeO
Cl
O Cl
7 N
N OMe
O Cl
MeO
5810b
14
HS
Cl
O Cl
14
O Cl
S 35, 57b
15
HS
Cl
Cl
O
15
O
S
Cl
85
b
a Yield after puriﬁcation by column chromatography. The rest is starting material.
b Trapping step performed at 60 C instead of rt.
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transition metaleligand ratios were screened by using Cy3P
(Cy¼cyclohexyl) in DMF at 130 C, and the best result was observed
using 5 mol % of Pd(OAc)2 and 10 mol % of phosphine (incomplete
conversion was noted using 20 mol % of Pd(OAc)2 and 10 mol % of
phosphine) (Table 3, entries 1e4). Using DMA or dioxane as solvent
or even a tetraalkylammonium chloride, as recommended by Kraus
and Kempema for the cyclization of bromo diaryl ketones,2c proved
less suitable.
These optimized conditions in hand, the ketones 2 and 3 were
involved in the reaction. Whereas the former led to the expected
methoxy-substituted azaﬂuorenone 17 in 69% yield (entry 5), only
4-azaﬂuorenone (16, 19%) was isolated alongside unidentiﬁed side
products using the latter (entry 6). Cyclization of 3-benzoyl-2-chloroquinoline (4) was achieved under the same reaction condi-
tions, affording 11H-indeno[1,2-b]quinolin-11-one (18) in 63% yield
(entry 8). In the case of 2-chloro-3-pyridyl 3-methoxyphenyl ke-
tone (8), for which two cyclization products are possible, the re-
action proved regioselective,18 the CeH bond activation occurring
para to the methoxy group in the course of the formation of the
tricycle 19 (entry 9). The structures of both 16 and 19 were con-
ﬁrmed unambiguously by X-ray diffraction (Fig. 2). As was observed
of its isomer 3, the reagent 9, expected to allow further coupling
thanks to the presence of a chloro group, did not afford the corre-
sponding chloro cyclized product. Indeed, 4-azaﬂuorenone (16)
was again the sole identiﬁable product obtained using Cy3P or tBu3P
(entries 10 and 11). The use of 10, in which the 2-chlorophenyl is
replaced by a 2-chloro-3-pyridyl, also failed to lead to the isolation
Fig. 2. ORTEP diagrams (50% probability) of compounds 16 and 19.
Table 3
Synthesis of the azaﬂuorenones 16e19 by intramolecular arylation
Pd(OAc)2 (x mol%)
L·HBF4 (y mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 hN Cl
O
X
R
2
4
3
N
O
X
4
3 R
Entry Substrate x L (y) Product Yielda (%)
1 1
N Cl
O 5 Cy3P (10) 16
N
O 87
2 5 Cy3P (15) 82
3 10 Cy3P (10) 81
4 20 Cy3P (10) 64b
5 2 (R¼OMe)
N Cl
O
R
5 Cy3P (10) 17
N
O
R
69c
6 3 (R¼Cl) 5 Cy3P (10) d dd
7 5 tBu3P (10) d de
8 4
N
COPh
Cl
5 Cy3P (10) 18
N
O
63b
9 8
N Cl
O
OMe
5 Cy3P (10) 19
N
O
OMe 60
b
10 9
N Cl
O Cl
5 Cy3P (10) d
N
O Cl df
11 5 tBu3P (10) d df
12 10
N Cl
O
N
Cl
5 Cy3P (10) d
N
N
O Cl
dg
a After puriﬁcation by column chromatography.
b Only organic product present in the crude.
c Compound 2 was also recovered in 10% yield.
d 8-Chloro-5H-indeno[1,2-b]pyridin-5-one was not obtained but 16 was isolated in 19% yield.
e 8-Chloro-5H-indeno[1,2-b]pyridin-5-one was not obtained but 16 was isolated in 8% yield.
f 6-Chloro-5H-indeno[1,2-b]pyridin-5-one was not obtained but 16 and 3-benzoylpyridine were isolated in 18 and 13% yields, respectively, among unidentiﬁed products.
g 6-Chloro-5H-pyrido[30 ,40:4,5]cyclopenta[1,2-b]pyridin-5-one was not obtained but 5H-pyrano[2,3-b:6,5-b0]dipyridin-5-one 20 was isolated in 70% yield (only organic
product present in the crude), see Scheme 1.
N. Marquise et al. / Tetrahedron 69 (2013) 10123e1013310126of an azaﬂuorenone (entry 12). Surprisingly, 5H-pyrano[2,3-b:6,5-
b0]dipyridin-5-one (20) was isolated instead in 70% yield
(Scheme 1), a result that could be attributed to the presence of
a carbonate reagent (vide infra).We next turned to the cyclization through intramolecular aryla-
tion of the ketones prepared from methoxypyridines (Table 4). The
diaryl ketone11, inwhich the chloro group is connected to thephenyl
component, led to the corresponding azaﬂuorenone, but did so less
20
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
10 70% yield
N
N Cl
Cl
N
O
O N
O
Scheme 1. Synthesis of 5H-pyrano[2,3-b:6,5-b0]dipyridin-5-one (20) from 10 and ORTEP diagram (50% probability) of compound 20.
N. Marquise et al. / Tetrahedron 69 (2013) 10123e10133 10127efﬁciently than either 1, 2, 4 or 8 (Table 3). Using a tetraalkylammo-
nium chloride, as recommended by Kraus and Kempema for the
cyclization of bromo diaryl ketones,2c we were able to isolate the
expectedmethoxy-substituted 9H-indeno[2,1-c]pyridin-9-one 21 in
48% yield (Table 4, entry 1). Various attempts to increase the yield byTable 4
Synthesis of the azaﬂuorenones 21 and 24 by intramolecular arylation
X Pd(OAc)2 (
L·HBF4 (10
K2CO3 (2
DMF, 130
OOMe
N(N)R (N)
Entry Substrate L
1 11 (X¼Cl)
N OMe
O X C
2 t
3 12 (X¼Br) C
4 t
5 13
N OMe
O
N
Cl
C
6 5
N OMe
O Cl
MeO
C
7 t
8 6
N
O ClOMe
C
9 7 N
N OMe
O Cl
MeO
C
a After puriﬁcation by column chromatography.
b Reaction performed in the presence of Pr4NCl (2 equiv).
c Lower conversion without Pr4NCl.
d Only organic product present in the crude.
e 1-Methoxy-9H-indeno[2,1-c]pyridin-9-one (21) was not obtained (see Scheme 2).
f The rest is starting material.
g 6-Methoxy-5H-pyrido[30 ,40:4,5]cyclopenta[1,2-b]pyridin-5-one was not obtained, se
h Compound 5 (34%) was recovered; an unidentiﬁed product also formed.
i 4-Methoxy-5H-indeno[1,2-b]pyridin-5-one was not obtained, see Scheme 5.
j 2,4-Dimethoxy-5H-indeno[1,2-d]pyrimidin-5-one was not obtained, see Scheme 6.recourse to cesium carbonate or sodium tert-butoxide as base or to
tolueneorDMAas solvent led to lower conversions. It isworthnoting
that using tBu3P in this case didnot lead to an azaﬂuorenone but only
to the cyclized demethylated azaxanthone 22 togetherwith thenon-
cyclized dechlorinated product 23 (entry 2, Scheme 2).5 mol%)
mol%)
equiv)
°C, 24 h
O
(N)
MeO
N(N)
R
Product Yielda (%)
y3P 21
N
O
OMe
48b,c,d
Bu3P de
y3P 40,b,f 61f
Bu3P 81b
y3P d
N
O
N
OMe
dg
y3P 24
N
O
OMeMeO
30h
Bu3P 21
y3P d
N
OMeO
di
y3P d
N
N OMeMeO
O d
j
e Scheme 3.
Fig. 3. ORTEP diagram (50% probability) of compound 24.
Pd(OAc)2 (5 mol%)
tBu3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
11
23: 12% yield
N OMe
O
Ph
+
22: 14% yield
N O
O
Scheme 2. Synthesis of 5H-benzopyrano[2,3-b]pyridin-5-one (22) from 11.
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sider the diaryl ketone 12, which bears a bromo group instead of
a chloro one. Its cyclization in the presence of Pr4NCl using either
Cy3P or tBu3P afforded the methoxy-substituted azaﬂuorenone 21
in 40 and 81% yields, respectively. It transpired that Pr4NCl was not
actually required since 21 could still be isolated in 61% yield using
Cy3P without this ammonium salt (entries 3 and 4). Replacing
K2CO3 by Cs2CO3 also allowed us to isolate 21 using toluene as
solvent (110 C), but in a low 20% yield.
We next turned to the cyclization of the diaryl ketone 13, which
differs from 11 in that the 2-chlorophenyl ring is replaced by a 2-
chloro-3-pyridyl one. As noted using 10, no azaﬂuorenone was
obtained, but instead the same azaxanthone 20was isolated in 79%
yield (the crude also contained recovered 13 and unidentiﬁed
products, entry 5, Scheme 3). The formation of 20 from both 10 (in
this case, the substitution of a chloro group by a carbonate is con-
sidered to explain the presence of oxygen in the product) and 13
through a common intermediate can be explained by the mecha-
nism depicted in Scheme 4.20
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
13 79% yield
N
N OMe
Cl
N
O
O N
O
Scheme 3. Synthesis of 5H-pyrano[2,3-b:6,5-b0]dipyridin-5-one (20) from 13.
20
10
O Pd O Pd
O
NN
R Cl
(II)
substitution and
oxidative addition
oxidative addition
13
R = CO2K: - CO2
- KCl
R = Me: - MeCl
N N
O
(II)
reductive
elimination
Scheme 4. Mechanism proposed to explain the formation of 5H-pyrano[2,3-b:6,5-b0]
dipyridin-5-one (20) from 10 and 13 through a common intermediate (ligands
omitted).As observed for 11, the cyclization of the dimethoxy ketone 5
furnished the expected 9H-indeno[2,1-c]pyridin-9-one 24 (Fig. 3).
However, the yield proved to be lower in the case of 24 since it was
isolated in 30 and 21% yields, respectively, using Cy3P and tBu3P as
ligand. The presence of a second electron-donating methoxy group
on the substrate 5 could be responsible for the reduced reactivity
observed; indeed, the ketone 5 was recovered in 34% yield using
Cy3P as ligand (entries 6 and 7).
Compared with 11, the ketone 6, for which the methoxy group
was moved from the 2- to the 4-position of the pyridine ring, gave
a different result. Indeed, when treated under the general cycliza-
tion conditions using Cy3P, no azaﬂuorenone was obtained, but
10H-benzopyrano[3,2-c]pyridin-10-one (25) formed instead in 31%yield. The presence of Pr4NCl improved this yield to 51% (25was the
only organic product present in the crude, entry 8, Table 4,
Scheme 5).
From the pyrimidyl ketone 7, neither an azaﬂuorenone nor an
azaxanthone was formed, but a complex mixture resulted instead.
Doubling the amount of catalyst led to a complete degradation of
the substrate. Crystals suitable for X-ray diffractionwere isolated in
this case and therefore allowed the pyrimidine ring-opening
product shown in Scheme 6 to be evidenced. To rationalize the
unexpected formation of 26, the plausible mechanistic sequence
depicted in Scheme 7 was proposed.
8H-Indeno[2,1-b]thiophen-8-one (27) has previously been efﬁ-
ciently synthesized by Campo and Larock from 3-(2-bromophenyl)
thiophene using palladium-catalyzed cyclocarbonylation.19 Start-
ing from 14, which bears the chloro group on the phenyl ring, both
Cy3P and tBu3P were tested as ligand in DMF at 130 C, affording 27
in 90 and 38% yields, respectively. Lower 35 and 17% yields were,
respectively, obtained from 15, for which the chloro group is
present on the thiophene ring (Table 5).3. Biological evaluation
A preliminary study has been carried out to investigate the cy-
totoxic potential of the ﬂuorenone derivatives 16, 17, 18, 21, 27 and
the azaxanthones 20 and 25. The anti-proliferative activity of the
derivatives was determined using breast cancer cell lines: MCF-7,
A549 human lung adenocarcinoma cells, and A2058 human mel-
anoma cells. MCF-7 is an invasive differentiated mammary epi-
thelial breast cancer cell line; A549 is an adenocarcinomic alveolar
epithelial cell line, and A2058 is a highly invasive and tumorigenic
epithelial melanoma cell line. These three cell lines are used
worldwide to screen and compare the anti-proliferative activity of
new molecules vs standard anticancer compounds. The molecules
tested fell short of exhibiting moderate-to-strong activity at 10 mM
with the selected cell lines, with none of the molecules causing
more than a 10% inhibition of growth. Because of structural simi-
larity with natural azaﬂuorenone antimicrobial agents such as
Onychine,2b the synthesized compounds 16, 17, 18, 21, and the
thioﬂuorenone analogue 27 were then screened for their antibac-
terial activity against a panel of Gram-positive and Gram-negative
reference strain bacteria (Escherichia coli ATCC25922, Salmonella
enterica serovar Typhimurium CIP5858, Pseudomonas aeruginosa
ATCC27853, Staphylococcus aureus ATCC25923, Bacillus subtilis
CIP52.62), and for their antifungal activity against pathogenic strain
26
7
OPd
OPd
O
N
N
MeCl
(II)
oxidative addition
hydrolysis
N
N
Me
O
(II)
reductive
elimination
OMe
O
Me
Cl
OPd
NMe
N
Me
O
(II) O
Cl
OPd
NMe
N
Me
O
(II) O
Cl
NPd
N
Me
O
(II)
Cl
O
CO
Me
Scheme 7. Mechanistic sequence proposed for the formation of 26.
25
Pd(OAc)2 (5 mol%)
Cy3P·HBF4 (10 mol%)
K2CO3 (2 equiv)
Pr4NCl (2 equiv)
DMF, 130 °C, 24 h
6
51% yield
N
Cl
N
OOMe
O
O
Scheme 5. Synthesis of 10H-benzopyrano[3,2-c]pyridin-10-one (25) from 6 and ORTEP diagram (50% probability) of compound 25.
26
Pd(OAc)2 (10 mol%)
Cy3P·HBF4 (20 mol%)
K2CO3 (2 equiv)
Pr4NCl (2 equiv)
DMF, 130 °C, 24 h
7
17% yield
N
N
OCl
OMe NMe
O
O
NHMeOMe
Scheme 6. Degradation of 7 under palladium catalysis and ORTEP diagram (50% probability) of compound 26.
Table 5
Synthesis of 8H-indeno[2,1-b]thiophen-8-one (27) by intramolecular arylation
Pd(OAc)2 (5 mol%)
L·HBF4 (10 mol%)
K2CO3 (2 equiv)
DMF, 130 °C, 24 h
O
14 or 15 S
27
Entry Substrate L Yielda (%)
1 14 O Cl
S
Cy3P 90
2 tBu3P 38b
3 15 O
S
Cl
Cy3P 35c
4 tBu3P 17d
a After puriﬁcation by column chromatography.
b The rest corresponds to recovered 14 but also to the formation of an unidentiﬁed product.
c The formation of 2-benzoylthiophene was also noted.
d The rest corresponds to recovered 15 but also to the formation of unidentiﬁed products.
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N. Marquise et al. / Tetrahedron 69 (2013) 10123e1013310130(Candida glabrata DSM6425). However, no antimicrobial activity
was detected against bacteria or yeast.
4. Conclusion
In summary, different heterocyclic diaryl ketones have been
synthesized by sequential deprotocuprationearoylation. For diaryl
ketone reagents bearing ahalogen at the2-position of oneof the aryl
groups cyclization under palladium catalysis was considered. In the
absence of a methoxy or a second chloro group at the position ad-
jacent to the ketone function, ﬂuorenones were obtained. The
presence of a second chloro groupwas not tolerated, and resulted in
mixtures containing dechlorinated products. The presence of
amethoxygroup led to loweryields ofﬂuorenones,withunexpected
xanthones being obtained in some cases. In the case of the dime-
thoxylated pyrimidyl ketone 7, ring-opening of the pyrimidine ring
was established. Lastly, efﬁcient thioﬂuorenone formation was
demonstrated, though the efﬁciency of this reaction proved to be
strongly dependent on the location of the chloro-substituent.
5. Experimental section
5.1. General
All reactions were performed in Schlenk tubes under an argon
atmosphere. THF was distilled over sodium/benzophenone. DMF
wasdriedover CaH2 anddistilledbeforeuse. Liquid chromatography
separations were achieved on silica gel Merck-Geduran Si 60
(63e200 mm). Nuclear magnetic resonance spectra were acquired
using Bruker AC-300 spectrometer (300MHzand75MHz for 1H and
13C, respectively). 1H chemical shifts (d) are given inparts permillion
(ppm) relative to the residual solvent peak, and 13C chemical shifts
relative to the central peak of the solvent signal. High-resolution
mass spectrometry measurements were performed at the Centre
Regional de Mesures Physiques de l’Ouest (CRMPO) in Rennes.
X-ray crystallography. The samples 16, 19, 20 and 24e26 were
studied with graphite monochromatized Mo-Ka radiation
(l¼0.71073 A). X-ray diffraction data were collected at T¼150(2) K
using APEXII, Bruker-AXS diffractometer. All structures were solved
by direct methods using the SIR97 program,20 and then reﬁned
with full-matrix least-square methods based on F2 (SHELX-97)21
with the aid of the WINGX program.22 All non-hydrogen atoms
were reﬁned with anisotropic atomic displacement parameters. H
atoms were ﬁnally included in their calculated positions. Molecular
diagrams were generated by ORTEP-3 (version 2.02).22 For B
a Nonius Kappa-CCD and an Oxford Cryostream low-temperature
device were used. Structure solution used direct methods,23 with
full-matrix least-squares reﬁnement based on F2.24 Non-hydrogen
atoms were reﬁned anisotropically and a riding model with ideal-
ized geometry employed for the reﬁnement of H atoms.
5.2. General procedure 1: deprotonation using the lith-
iumecopper base prepared from CuCl (1 equiv) and LiTMP
(2 equiv) before trapping with an aroyl chloride
A stirred cooled (0 C) solution of LiTMP prepared at 0 C in THF
(6 mL) from 2,2,6,6-tetramethylpiperidine (1.7 mL, 10 mmol) and
BuLi (1.6 M hexanes solution, 10 mmol) was treated with TMEDA
(0.77 mL, 5.0 mmol) and CuCl (495 mg, 5.0 mmol). The mixture was
stirred for 15 min at 0 C before introduction of the required sub-
strate (5 mmol). After 2 h at rt, a solution of the required aroyl
chloride (10 mmol) in THF (3 mL) was added. The mixture was
stirred at rt or 60 C overnight before addition of a 1 M aqueous
solution of NaOH (20 mL) and extraction with Et2O (220 mL).
After washing the organic phase with an aqueous saturated solu-
tion of NH4Cl (10 mL) and drying over anhydrous Na2SO4, thesolvent was evaporated under reduced pressure, and the product
was isolated after puriﬁcation by ﬂash chromatography on silica gel
(the eluent is given in the product description).
5.2.1. 2-Chloro-3-pyridyl phenyl ketone (1).10b Compound 1 was
prepared from 2-chloropyridine (using benzoyl chloride) and was
isolated (eluent: 9:1 heptane/AcOEt) as a yellow oil (yield: 90%): 1H
NMR(300MHz,CDCl3) d7.38 (dd,1H, J¼7.5 and4.9Hz), 7.42e7.50 (m,
2H), 7.61 (tt, 1H, J¼7.4 and 1.3 Hz), 7.72 (dd, 1H, J¼7.5 and 2.0 Hz),
7.75e7.81 (m, 2H), 8.52 ppm (dd, 1H, J¼4.9 and 2.0 Hz). 13C NMR
(75 MHz, CDCl3) d 122.3 (CH), 128.9 (2CH), 130.0 (2CH), 134.3 (CH),
134.9 (C),135.7 (C),138.0 (CH),147.7 (C),150.9 (CH),193.3ppm(C]O).
5.2.2. 2-Chloro-3-pyridyl 4-methoxyphenyl ketone (2). Compound 2
was prepared from 2-chloropyridine (using 4-methoxybenzoyl
chloride) and was isolated (eluent: 8:2 heptane/AcOEt) as a yellow
powder (yield: 80%): mp 79 C; 1H NMR (300 MHz, CDCl3) d 3.89 (s,
3H), 6.96 (d, 2H, J¼9.0Hz), 7.38 (dd,1H, J¼7.5 and4.8Hz), 7.72 (dd,1H,
J¼7.5 and 1.9 Hz), 7.78 (d, 2H, J¼4.8 Hz), 8.54 ppm (s, 1H); 13C NMR
(75MHz, CDCl3) d 55.8 (CH3),114.3 (2CH),122.4 (CH),128.9 (C),132.7
(2CH),135.5 (C),137.8 (CH),147.8 (C),150.7 (CH),164.6 (C),192.0 ppm
(C]O). These NMR data are analogous to those described
previously.25
5.2.3. 4-Chlorophenyl 2-chloro-3-pyridyl ketone (3). Compound 3
was prepared from 2-chloropyridine (using 4-chlorobenzoyl chlo-
ride) and was isolated (eluent: 8:2 heptane/AcOEt) as a yellow
powder (yield: 80%): mp 56 C; 1H NMR (300 MHz, CDCl3) d 7.40
(dd, 1H, J¼7.5 and 4.8 Hz), 7.44e7.48 (m, 2H), 7.71e7.76 (m, 3H),
8.57 (dd, 1H, J¼4.8 and 1.9 Hz); 13C NMR (75 MHz, CDCl3) d 122.5
(CH), 129.4 (2CH), 131.4 (2CH), 134.2 (C), 134.6 (C), 138.1 (CH), 141.0
(C), 147.8 (C), 151.2 (CH), 192.3 ppm (C]O). These NMR data are
analogous to those described previously.26
5.2.4. 2-Chloro-3-benzoylquinoline (4).10c Compound 4 was pre-
pared from 2-chloroquinoline (using benzoyl chloride) and was
isolated (eluent: 7:3 heptane/AcOEt) as a beige powder (yield: 44%):
mp 98 C; 1H NMR (300MHz, CDCl3) d 7.43e7.48 (m, 2H), 7.55e7.61
(m, 2H), 7.77e7.84 (m, 4H), 8.05 (d, 1H, J¼8.5 Hz), 8.18 ppm (s, 1H);
13C NMR (75 MHz, CDCl3) d 126.0 (C), 127.9 (CH), 128.1 (CH), 128.5
(CH),128.8 (2CH),130.1 (2CH),131.9 (CH),132.4 (C),134.1 (CH),136.2
(C), 138.5 (CH), 146.5 (C), 147.9 (C), 193.3 ppm (C]O).
5.2.5. 2-Chlorophenyl 2,6-dimethoxy-3-pyridyl ketone (5).10b
Compound 5 was prepared from 2,6-dimethoxypyridine (using 2-
chlorobenzoyl chloride) and was isolated (eluent: 9:1 heptane/
AcOEt) as a yellow powder (yield: 91%): mp 55 C; 1H NMR
(300 MHz, CDCl3) d 3.81 (s, 3H), 3.98 (s, 3H), 6.37 (d, 1H, J¼8.4 Hz),
7.31e7.37 (m, 4H), 7.98 ppm (d, 1H, J¼8.4 Hz); 13C NMR (75 MHz,
CDCl3) d 54.0 (CH3), 54.2 (CH3), 102.7 (CH), 113.1 (C), 126.8 (CH),
128.7 (CH), 129.6 (CH), 130.6 (CH), 130.9 (C), 141.1 (C), 144.1 (CH),
163.0 (C), 166.3 (C), 192.1 ppm (C]O).
5.2.6. 2-Chlorophenyl 4-methoxy-3-pyridyl ketone (6).10b
Compound 6 was prepared from 4-methoxypyridine (using 2-
chlorobenzoyl chloride) and was isolated (eluent: 2:8 heptane/
AcOEt) as a yellow powder (yield: 57%): mp 107 C; 1H NMR
(300MHz, C6D6) d 3.76 (s, 3H), 6.95e7.05 (m,1H), 7.31e7.43 (m, 3H),
7.45e7.49 (m, 1H), 8.42e9.76 (br m, 2H); 13C NMR (75 MHz, C6D6)
d 55.0 (CH3), 108.8 (C), 126.7 (CH), 128.3 (CH), 130.1 (CH), 130.1 (CH),
131.3 (CH), 132.1 (C), 140.8 (C), 152.7 (CH), 154.5 (CH), 164.1 (C),
192.3 ppm (C]O).
5.2.7. 2-Chlorophenyl 2,4-dimethoxypyrimidin-5-yl ketone (7).10b
Compound 7 was prepared from 2,4-dimethoxypyrimidine (using
2-chlorobenzoyl chloride) and was isolated (eluent: 8:2 heptane/
N. Marquise et al. / Tetrahedron 69 (2013) 10123e10133 10131AcOEt) as an orange powder (yield: 58%): mp 74 C; 1H NMR
(300 MHz, CDCl3) d 3.91 (s, 3H), 4.06 (s, 3H), 7.31e7.44 (m, 4H),
8.62 ppm (br s, 1H); 13C NMR (75 MHz, CDCl3) d 54.7 (CH3), 55.7
(CH3), 114.1 (C), 127.0 (CH), 129.4 (CH), 129.9 (CH), 131.3 (C), 131.6
(CH), 139.4 (C), 163.4 (CH), 167.0 (C), 169.6 (C), 190.8 ppm (C]O).
5.2.8. 2-Chloro-3-pyridyl 3-methoxyphenyl ketone (8). Compound 8
was prepared from 2-chloropyridine (using 3-methoxybenzoyl
chloride) and was isolated (eluent: 8:2 heptane/AcOEt) as an or-
ange powder (yield: 66%): mp 62 C; 1H NMR (300 MHz, CDCl3)
d 3.72 (s, 3H), 7.05 (ddd, 1H, J¼8.1, 2.6 and 1.0 Hz), 7.13 (ddd, 1H,
J¼7.6, 2.6 and 1.3 Hz), 7.22e7.30 (m, 3H), 7.63 (dd, 1H, J¼7.5 and
1.9 Hz), 8.41 (d, 1H, J¼4.6 Hz); 13C NMR (75 MHz, CDCl3) d 55.6
(CH3), 113.6 (CH), 120.9 (CH), 122.3 (CH), 123.3 (CH), 129.9 (CH),
135.0 (C), 137.2 (CH), 137.9 (C), 147.8 (C), 150.9 (CH), 160.1 (C),
193.2 ppm (C]O); HRMS (ESI): m/z calcd for C13H1035ClNaNO2
[(MþNa)þ] 270.0298, found 270.0298.
5.2.9. 2-Chlorophenyl 2-chloro-3-pyridyl ketone (9).12 Compound 9
was prepared from 2-chloropyridine (using 2-chlorobenzoyl chlo-
ride) and was isolated (eluent: 9:1 heptane/AcOEt) as an orange oil
(yield: 59%): 1H NMR (300 MHz, CDCl3) d 7.35e7.51 (m, 4H), 7.57
(dd, 1H, J¼7.6 and 1.7 Hz), 7.88 (dd, 1H, J¼7.6 and 2.0 Hz), 8.52 ppm
(dd, 1H, J¼4.8 and 2.0 Hz); 13C NMR (75 MHz, CDCl3) d 122.7 (CH),
127.3 (CH), 130.9 (CH), 131.2 (CH), 132.8 (C), 133.3 (CH), 134.9 (C),
137.1 (C), 139.5 (CH), 148.6 (C), 151.8 (CH), 193.1 ppm (C]O); HRMS
(ESI): m/z calcd for C12H735Cl2NNaO [(MþNa)þ] 273.9802, found
273.9805.
5.2.10. Bis(2-chloro-3-pyridyl) ketone (10). Compound 10 was pre-
pared from 2-chloropyridine (using 2-chloronicotinoyl chloride)
and was isolated (eluent: 7:3 heptane/AcOEt) as a yellow powder
(yield: 65%): mp 109 C; 1H NMR (300 MHz, CDCl3) d 7.43 (dd, 2H,
J¼7.5 and 4.8 Hz), 7.98 (dd, 2H, J¼7.5 and 1.8 Hz), 8.59 ppm (br s,
2H); 13C NMR (75 MHz, CDCl3) d 122.8 (2CH), 134.1 (2C), 139.8
(2CH), 148.5 (2C), 152.3 (2CH), 192.2 ppm (C]O). These NMR data
are analogous to those described previously.27
5.2.11. 2-Chlorophenyl 2-methoxy-3-pyridyl ketone (11).12
Compound 11 was prepared from 2-methoxypyridine (using 2-
chlorobenzoyl chloride) and was isolated (eluent: 9:1 heptane/
AcOEt) as a yellow powder (yield: 56%): mp 65 C; 1H NMR
(300 MHz, CDCl3) d 3.81 (s, 3H), 7.01 (dd, 1H, J¼7.5 and 4.9 Hz),
7.31e7.41 (m, 3H), 7.44e7.47 (m,1H), 7.99 (dd,1H, J¼7.5 and 2.0 Hz),
8.34 ppm (dd, 1H, J¼4.9 and 2.0 Hz); 13C NMR (75 MHz, CDCl3)
d 53.9 (CH3), 117.1 (CH), 121.8 (C), 126.9 (CH), 129.7 (CH), 129.9 (CH),
131.5 (CH), 131.6 (C), 139.7 (C), 140.6 (CH), 151.3 (CH), 162.2 (C),
193.7 ppm (C]O); HRMS (ESI): m/z calcd for C13H1135ClNO2
[(MþH)þ] and C13H1035ClNNaO2 [(MþNa)þ] 248.0478 and 270.0298,
found 248.0483 and 270.0298, respectively.
5.2.12. 2-Bromophenyl 2-methoxy-3-pyridyl ketone (12).
Compound 12 was prepared from 2-methoxypyridine (using 2-
bromobenzoyl chloride) and was isolated (eluent: 9:1 heptane/
AcOEt) as a yellow powder (yield: 43%): mp 80 C; 1H NMR
(300 MHz, CDCl3) d 3.82 (s, 3H), 6.94 (dd, 1H, J¼7.5 and 4.9 Hz),
7.28e7.35 (m, 1H), 7.38e7.40 (m, 2H), 7.62 (dd, 1H, J¼7.5 and
0.9 Hz), 8.03 (dd, 1H, J¼7.5 and 2.0 Hz), 8.38 ppm (dd, 1H, J¼4.9 and
2.0 Hz); 13C NMR (75 MHz, CDCl3) d 53.9 (CH3), 117.1 (CH), 119.6 (C),
121.2 (C), 127.4 (CH), 129.5 (CH), 131.5 (CH), 133.1 (CH), 140.9 (CH),
141.7 (C), 151.5 (CH), 162.2 (C), 194.3 ppm (C]O); HRMS (ESI): m/z
calcd for C13H1079BrNNaO2 [(MþNa)þ] 313.9793, found 313.9795.
5.2.13. 2-Chloro-3-pyridyl 2-methoxy-3-pyridyl ketone (13).
Compound 13 was prepared from 2-methoxypyridine (using 2-
chloronicotinoyl chloride) and was isolated (eluent: 8:2heptane/AcOEt) as a yellow powder (yield: 39%): mp 87 C; 1H
NMR (300 MHz, CDCl3) d 3.79 (s, 3H), 7.08 (dd, 1H, J¼7.5 and
4.9 Hz), 7.38 (br m, 1H), 7.82 (dd, 1H, J¼7.5 and 1.4 Hz), 8.14 (dd,
1H, J¼7.5 and 2.0 Hz), 8.40 (dd, 1H, J¼4.9 and 2.0 Hz), 8.52 ppm
(br m, 1H); 13C NMR (75 MHz, CDCl3) d 54.1 (CH3), 117.5 (CH),
120.9 (C), 122.5 (CH), 136.6 (C), 138.2 (CH), 140.7 (CH), 147.7 (C),
150.7 (CH), 152.1 (CH), 162.1 (C), 192.0 ppm (C]O); HRMS (ESI):
m/z calcd for C12H935ClN2NaO2 [(MþNa)þ] 271.0250, found
271.0251.
5.2.14. 2-Chlorophenyl 2-thienyl ketone (14). Compound 14 was
prepared from thiophene (using 2-chlorobenzoyl chloride, trapping
step at 60 C) and was isolated (eluent: 97:3 heptane/AcOEt) as an
orange oil (yield: 57%): 1H NMR (300 MHz, CDCl3) d 7.12 (dd, 1H,
J¼4.9 and 3.8 Hz), 7.33e7.49 (m, 5H), 7.76 ppm (dd, 1H, J¼4.9 and
1.2 Hz); 13C NMR (75 MHz, CDCl3) d 126.7 (CH), 128.4 (CH), 128.0
(CH), 130.4 (CH), 131.3 (C), 131.4 (CH), 135.8 (CH), 136.1 (CH), 138.5
(C), 143.8 (C), 187.2 ppm (C]O). These NMR data are analogous to
those described previously.28
5.2.15. 3-Chloro-2-thienyl phenyl ketone (15).12 Compound 15 was
prepared from 3-chlorothiophene (using benzoyl chloride, trapping
step at 60 C) and was isolated (eluent: 9:1 heptane/AcOEt) as
a yellow viscous oil (yield: 85%): 1H NMR (300 MHz, CDCl3) d 6.99
(d, 1H, J¼5.2 Hz), 7.43e7.46 (m, 2H), 7.54e7.60 (m, 2H),
7.81e7.83 ppm (m, 2H); 13C NMR (75 MHz, CDCl3) d 128.4 (2CH),
129.6 (2CH), 130.1 (CH), 130.7 (CH), 133.0 (CH), 134.3 (C), 137.8 (C),
187.8 ppm (C]O), one C not seen; HRMS (ESI): m/z calcd for
C11H835ClOS [(MþH)þ] and C11H735ClNaOS [(MþNa)þ] 222.9984 and
244.9804, found 222.9999 and 244.9803, respectively.
5.3. General procedure used for the cyclization step
A degassed mixture of K2CO3 (0.28 g, 2.0 mmol), Pd(OAc)2 (the
amount is given in the product description), the ligand (its nature
and the amount is given in the product description), the required
ketone (1.0 mmol), and in some cases Pr4NCl (0.44 g, 2 mmol), in
DMF (4 mL) was heated at 130 C for 24 h. After ﬁltration over
a Celite pad, washing using CH2Cl2 (310 mL), and removal of the
solvent under reduced pressure, the product was isolated after
puriﬁcation by ﬂash chromatography on silica gel (the eluent is
given in the product description).
5.3.1. 5H-Indeno[1,2-b]pyridin-5-one (16). Compound 16 was ob-
tained from 1 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg) and
Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated (eluent:
8:2 heptane/AcOEt) as a yellow powder (yield: 87%): mp 138 C
(lit.29 137e138 C); 1H NMR (300 MHz, CDCl3) d 7.21 (1H, dd, J¼7.4
and 5.1 Hz), 7.44 (1H, td, J¼7.5 and 0.9 Hz), 7.61 (1H, td, J¼7.5 and
1.1 Hz), 7.73 (1H, ddd, J¼7.5, 1.1 and 0.9 Hz), 7.86 (1H, dt, J¼7.5 and
0.9 Hz), 7.90 (1H, dd, J¼7.4 and 1.6 Hz), 8.61 ppm (1H, dd, J¼5.1 and
1.6 Hz); 13C NMR (75 MHz, CDCl3) d 121.0 (CH), 123.4 (CH), 124.3
(CH),128.5 (C),131.1 (CH),131.4 (CH),134.8 (C), 135.4 (CH),143.6 (C),
154.0 (CH), 165.1 (C), 191.8 ppm (C]O). These NMR data are anal-
ogous to those described previously.30
X-ray data for compound 16: C12H7NO, M¼181.19, monoclinic,
P21/c, a¼12.068(3), b¼5.1986(15), c¼14.465(3) A, b¼108.686(13),
V¼859.7(4) A3, Z¼4, rc¼1.4 g cm3, m¼0.090 mm1. A ﬁnal re-
ﬁnement on F2 with 1964 unique intensities and 128 parameters
converged at uR(F2)¼0.0996 (R(F)¼0.0452) for 1460 observed re-
ﬂections with I>2s(I). CCDC 944094.
5.3.2. 8-Methoxy-5H-indeno[1,2-b]pyridin-5-one (17).12 Compound
17 was prepared from 2 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg)
and Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated
(eluent: 8:2 heptane/AcOEt) as a yellow powder (yield: 69%): mp
N. Marquise et al. / Tetrahedron 69 (2013) 10123e1013310132113 C; 1H NMR (300 MHz, CDCl3) d 3.96 (s, 3H), 6.92 (dd, 1H, J¼8.3
and 2.3 Hz), 7.24 (dd,1H, J¼7.4 and 5.1 Hz), 7.41 (d,1H, J¼2.3 Hz), 7.7
(d, 1H, J¼8.3 Hz), 7.89 (dd, 1H, J¼7.4 and 1.6 Hz), 8.62 ppm (dd, 1H,
J¼5.1 and 1.6 Hz); 13C NMR (75MHz, CDCl3) d 56.1 (CH3), 106.4 (CH),
116.7 (CH), 123.7 (CH), 126.4 (CH), 127.8 (C), 129.8 (C), 131.2 (CH),
146.5 (C), 153.4 (CH), 164.2 (C), 166.1 (C), 190.3 ppm (C]O); HRMS
(ESI): m/z calcd for C13H9NNaO2 [(MþNa)þ] 234.0531, found
234.0534.
5.3.3. 11H-Indeno[1,2-b]quinolin-11-one (18). Compound 18 was
obtained from 4 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg) and
Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated (eluent:
8:2 heptane/AcOEt) as a yellow powder (yield: 63%): mp 173 C
(lit.29 176 C); 1H NMR (300 MHz, CDCl3) d 7.49e7.56 (2H, m), 7.69
(1H, td, J¼7.5 and 1.1 Hz), 7.82 (1H, td, J¼7.0 and 1.4 Hz), 7.84 (1H, dt,
J¼7.5 and 0.7 Hz), 7.88 (1H, dd, J¼8.2 and 1.2 Hz), 8.11e8.16 (2H, m),
8.4 (s, 1H); 13C NMR (75 MHz, CDCl3) d 121.9 (CH), 124.2 (CH), 127.1
(C), 127.3 (CH), 127.7 (C), 129.9 (CH), 130.6 (CH), 131.6 (CH), 132.1
(CH), 132.5 (CH), 135.6 (CH), 137.5 (C), 143.9 (C), 150.7 (C), 162.1 (C),
190.9 ppm (C]O). The 1H NMR data are analogous to those de-
scribed previously.31
5.3.4. 7-Methoxy-5H-indeno[1,2-b]pyridin-5-one (19). Compound
19 was prepared from 8 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg)
and Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated
(eluent: 8:2 heptane/AcOEt) as an orange powder (yield: 60%): mp
190 C; 1H NMR (300 MHz, CDCl3) d 3.82 (s, 3H), 7.07e7.15 (m, 2H),
7.18 (d, 1H, J¼2.4 Hz), 7.79 (d, 1H, J¼8.2 Hz), 7.84 (dd, 1H, J¼7.4 and
1.6 Hz), 8.53 (dd, 1H, J¼5.2 and 1.4 Hz); 13C NMR (75 MHz, CDCl3)
d 55.9 (CH3), 109.4 (CH), 120.9 (CH), 122.3 (CH), 122.5 (CH), 128.6
(CH), 131.4 (CH), 135.9 (C), 136.8 (C), 153.8 (CH), 162.5 (C), 165.5 (C),
191.7 (C]O); HRMS (ESI): m/z calcd for C13H9NNaO2 [(MþNa)þ]
234.0531, found 234.0531.
X-ray data for compound 19: C13H9NO2, M¼211.21, monoclinic,
P21/a, a¼15.323(3), b¼3.8645(7), c¼17.224(3) A, b¼112.183(6),
V¼944.4(3) A3, Z¼4, rc¼1.485 g cm3, m¼0.102 mm1. A ﬁnal re-
ﬁnement on F2 with 2082 unique intensities and 147 parameters
converged at uR(F2)¼0.1524 (R(F)¼0.0569) for 1532 observed re-
ﬂections with I>2s(I). CCDC 944095.
5.3.5. 5H-Pyrano[2,3-b:6,5-b0]dipyridin-5-one (20). Compound 20
was prepared from 10 or 13 (using Pd(OAc)2 (5 mol %, 50 mmol,
11 mg) and Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was
isolated (eluent: 7:3 heptane/AcOEt) as a yellow powder (yield: 70
or 79%, respectively): mp 240 C (lit.27 240 C); 1H NMR (300 MHz,
CDCl3) d 7.50 (dd, 2H, J¼7.8 and 4.6 Hz), 8.70 (dd, 2H, J¼7.8 and
2.1 Hz), 8.83 ppm (dd, 2H, J¼4.6 and 2.1 Hz); 13C NMR (75 MHz,
CDCl3) d 116.7 (2C), 121.8 (2CH), 137.4 (2CH), 155.1 (2CH), 160.3 (2C),
178.0 ppm (C]O). The 1H NMR data are analogous to those de-
scribed previously.27
X-ray data for compound 20: 2(C11H6N2O2), M¼396.36, mono-
clinic, Pc, a¼3.7934(8), b¼20.911(4), c¼10.908(2)A, b¼97.678(10),
V¼857.5(3) A3, Z¼2, rc¼1.535 g cm3, m¼0.109 mm1. A ﬁnal re-
ﬁnement on F2 with 2910 unique intensities and 271 parameters
converged at uR(F2)¼0.0876 (R(F)¼0.0416) for 2263 observed re-
ﬂections with I>2s(I). CCDC 944096.
5.3.6. 1-Methoxy-9H-indeno[2,1-c]pyridin-9-one (21).12 Compound
21was prepared from 12 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg)
and tBu3P$HBF4 (10 mol %, 0.10 mmol, 29 mg)) and was isolated
(eluent: 8:2 heptane/AcOEt) as a yellow powder (yield: 81%): mp
160 C; 1H NMR (300 MHz, CDCl3) d 4.13 (s, 3H), 7.15 (d, 1H,
J¼5.0 Hz), 7.44 (td, 1H, J¼7.2 and 1.6 Hz), 7.49e7.60 (m, 2H), 7.71
(ddd, 1H, J¼7.2, 1.1 and 0.8 Hz), 8.37 (d, 1H, J¼5.0 Hz); 13C NMR
(75 MHz, CDCl3) d 54.4 (CH3), 109.8 (CH), 113.4 (C), 121.5 (CH), 124.3
(CH),131.5 (CH),134.1 (C), 134.2 (CH),141.1 (C), 155.0 (CH), 156.4 (C),161.0 (C), 191.5 (C]O); HRMS (ESI): m/z calcd for C13H9NNaO2
[(MþNa)þ] 234.0531, found 234.0532.
5.3.7. 5H-Benzopyrano[2,3-b]pyridin-5-one (22). Compound 22
was prepared from 11 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg)
and tBu3P$HBF4 (10 mol %, 0.10 mmol, 29 mg)) and was isolated
(eluent: 8:2 heptane/AcOEt) as a yellow powder (yield: 14%): mp
180 C (lit.32 178e179 C); 1H NMR (300 MHz, CDCl3) d 7.45e7.57
(m, 2H), 7.62 (dd,1H, J¼8.4 and 0.6 Hz), 7.79 (ddd,1H, J¼8.4, 6.9 and
1.5 Hz), 8.32 (dd, 1H, J¼8.1 and 1.8 Hz), 8.72 (dd, 1H, J¼7.8 and
1.8 Hz), 8.75 (br s, 1H); 13C NMR (75 MHz, CDCl3) d 116.9 (C), 118.7
(CH), 121.3 (CH), 121.7 (C), 124.8 (CH), 126.8 (CH), 135.8 (CH), 137.5
(CH), 154.3 (CH), 155.9 (C), 160.5 (C), 177.8 (C). These NMR data are
analogous to those described previously.32
5.3.8. 2-Methoxy-3-pyridyl phenyl ketone (23). Compound 23 was
prepared from11 (usingPd(OAc)2 (5mol%,50mmol,11mg)and tBu3P$
HBF4 (10mol %, 0.10mmol, 29mg)) andwas similarly isolated (yield:
12%). The analyses are analogous to those described previously.10b
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(24). Compound 24was prepared from 5 (using Pd(OAc)2 (5 mol %,
50 mmol, 11 mg) and Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and
was isolated (eluent: 8:2 heptane/AcOEt) as a yellow powder
(yield: 30%): mp 166 C; 1H NMR (300 MHz, CDCl3) d 4.02 (s, 3H),
4.1 (s, 3H), 6.52 (s, 1H), 7.36e7.51 (m, 3H), 7.70 (d, 1H, J¼7.1 Hz); 13C
NMR (75 MHz, CDCl3) d 54.2 (CH3), 54.6 (CH3), 96.1 (CH), 106.8 (C),
121.3 (CH), 123.7 (CH), 131.1 (CH), 133.4 (CH), 136.3 (C), 140.3 (C),
158 (C), 160.5 (C), 168.3 (C), 189.3 (C]O); HRMS (ESI):m/z calcd for
C14H11NNaO3 [(MþNa)þ] 264.0637, found 264.0635.
X-ray data for compound 24: C14H11NO3, M¼241.24, monoclinic,
P21/n, a¼5.2623(4), b¼17.1350(9), c¼12.1808(9) A, b¼93.170(3),
V¼1096.66(13) A3, Z¼4, rc¼1.461 g cm3, m¼0.104 mm1. A ﬁnal
reﬁnement on F2 with 2506 unique intensities and 166 parameters
converged at uR(F2)¼0.0962 (R(F)¼0.0397) for 2049 observed re-
ﬂections with I>2s(I). CCDC 944097.
5.3.10. 10H-Benzopyrano[3,2-c]pyridin-10-one (25). Compound 25
was prepared from 6 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg) and
Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated (eluent:
1:1 heptane/AcOEt) as awhite powder (yield: 51%):mp 185 C (lit.33
184 C); 1H NMR (300MHz, CDCl3) d 7.40e7.54 (m, 3H), 7.79 (dt, 1H,
J¼7.2 and 1.7 Hz), 8.34 (dd, 1H, J¼7.8 and 1.7 Hz), 8.82 (d, 1H,
J¼5.2 Hz), 9.52 (s, 1H). These data are in accordance with the liter-
ature.33 13C NMR (75 MHz, CDCl3) d 112.8 (CH), 118.3 (CH), 123.1 (C),
125.2 (CH), 126.9 (CH), 135.8 (CH), 150.6 (CH), 153.8 (CH), 156.0 (C),
161.3 (C), 176.3 (C), 191.3 ppm (C]O).
X-ray data for compound 25: C12H7NO2, M¼197.19, orthorhom-
bic, Pc21b, a¼5.1389(5), b¼8.3386(7), c¼20.173(2) A,
V¼864.44(14) A3, Z¼4, rc¼1.515 g cm3, m¼0.105 mm1. A ﬁnal
reﬁnement on F2 with 1664 unique intensities and 136 parameters
converged at uR(F2)¼0.1816 (R(F)¼0.0645) for 1509 observed re-
ﬂections with I>2s(I). CCDC 944098.
5.3.11. 1,4-Dihydro-N,1-dimethyl-4-oxo-3-quinolinecarboxamide
(26). Compound 26was obtained from 7 (using Pd(OAc)2 (10mol %,
0.1 mmol, 22 mg) and Cy3P$HBF4 (20 mol %, 0.20 mmol, 74 mg)).
X-ray data for compound 26: C12H12N2O2,M¼216.24, monoclinic,
P21/n, a¼4.7522(4), b¼13.1688(12), c¼16.4679(14)A, b¼96.766(4),
V¼1023.40(15) A3, Z¼4, rc¼1.403 g cm3, m¼0.098 mm1. A ﬁnal
reﬁnement on F2 with 2305 unique intensities and 147 parameters
converged at uR(F2)¼0.1047 (R(F)¼0.0372) for 1962 observed re-
ﬂections with I>2s(I). CCDC 944099.
5.3.12. 8H-Indeno[2,1-b]thiophen-8-one (27).12 Compound 27 was
prepared from 14 (using Pd(OAc)2 (5 mol %, 50 mmol, 11 mg) and
N. Marquise et al. / Tetrahedron 69 (2013) 10123e10133 10133Cy3P$HBF4 (10 mol %, 0.10 mmol, 37 mg)) and was isolated (eluent:
8:2 heptane/AcOEt) as an orange powder (yield: 38%): mp 106 C
(lit.34 107e109 C); 1H NMR (300 MHz, CDCl3) d 7.11e7.19 (m, 3H),
7.31e7.36 (m, 1H), 7.46e7.49 (m, 1H), 7.73 ppm (d, 1H, J¼4.7 Hz); 13C
NMR (75MHz, CDCl3) d 119.7 (CH),120.3 (CH),124.2 (CH),128.3 (CH),
133.8 (CH), 137.2 (C), 138.0 (C), 139.4 (CH), 139.8 (C), 158.9 (C),
185.7 ppm (C]O).
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